GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update.

Conference Call Information:

Date:	Wednesday, November 10
Time:	8:30 am Eastern Time
Domestic Dial-in:	(844) 615-6509
International Dial-in:	(918) 922-3148
Conference ID:	5783655
Webcast:	https://edge.media-server.com/mmc/p/zgrrmubx

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn

Follow @AltimmuneInc on Twitter

Investor and Media Contact:

Will Brown

Chief Financial Officer

Phone: 240-654-1450

wbrown@altimmune.com

Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021